Dry Eye

Mile Brujic, OD, FAAO, shares considerations from a patient case, highlighting diagnostic tools in dry eye disease as well as the ability of the patient to use medication.

Mile Brujic, OD, FAAO, presents the case of a 42-year-old female patient with dry eye disease who has discomfort using eyedrops.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

Dual-purpose therapeutics help patients with both conditions.

Knowing the approach to each step of ocular management can optimize patient vision.

The investigators explained that the platform delivers energy that differentially heats the tissue by the impedance of the electromagnetic current.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Selina McGee, OD, FAAO, emphasizes the significance of a multifactorial treatment approach for dry eye, especially in patients concurrently using other eye drops or contact lenses, and advocates for ocular sparing therapies when needed.

Selina McGee, OD, FAAO, reviews a challenging case involving a patient with advanced glaucoma on multiple medications, grappling with multifactorial dry eye.

Selina McGee, OD, FAAO, shares her comprehensive examination and treatment approach, underscoring the importance of tailoring treatments based on the individual's dry eye evaluation.

Selina McGee, OD, FAAO, presents a patient case referred for ocular surface optimization in preparation for cataract surgery.

Physicians ask the right questions and take an aggressive approach to treatment.

Managing dry eye disease often is key to patient comfort.

Combining simple and advanced methods can lead to optimal patient outcomes.

Approaching dry eye disease holistically will empower patients to take charge with personalized home health solutions.

Proper management results in better expectations, outcomes for patients.

Prevent Blindness aims to educate the public on dry eye through free resources including fact sheets and social media graphics for Dry Eye Awareness Month.

The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.

Ahmad M. Fahmy, OD, FAAO, Dipl ABO, gives highlights of his AOA 2023 poster that was a pooled analysis of the Gobi and Mojave studies relevant to perfluorohexyloctane (NOV03) for dry eye disease associated with Meibomian gland dysfunction.

This 3-pronged approach for nutritional intervention to help maintain dry eye disease is in addition to a recommended dietary intake of daily oily fish.

When dry eye treatments are not working for your patient’s symptoms or the anterior segment exam looks normal, you must ask yourself: What if the symptoms are secondary to a neurologic dysfunction in pain perception?

Bruder Healthcare expands their dry eye portfolio by entering a distribution agreement with AllerFocus for its Percutaneous Allergy Test.

Jessilin Quint, OD, MBA, MS, FAAO, shares the latest and greatest in the world of dry eye, from new technology to how clinicians can start in on dry eye therapy today.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

The water-free, preservative-free, anti-inflammatory drop from Novaliq, now coined Vevye, received FDA approval to treat the signs and symptoms of dry eye disease.